文献速递临床试验与 GCP

维生素D与镁补充对COVID-19患者临床症状及血清炎症和氧化应激标志物的影响:一项随机对照试验研究方案的结构化摘要

The effect of vitamin D and magnesium supplementation on clinical symptoms and serum inflammatory and oxidative stress markers in patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2023-02-06

本研究为4臂随机双盲安慰剂对照析因设计临床试验,纳入伊朗Shahid Mohammadi医院18至65岁经RT-PCR确诊的COVID-19住院患者104例,随机分为维生素D加镁、维生素D加镁安慰剂、镁加维生素D安慰剂、双安慰剂四组各26例,干预3周,评估临床症状缓解及CRP、MDA、TAC等血清标志物。

要点

  • 4臂随机双盲安慰剂对照析因试验,干预3周,每组26例。
  • 纳入标准包括呼吸频率大于30次/分且室内空气氧饱和度低于93%。
  • 主要结局为症状缓解及CRP、MDA、TAC、25羟维生素D、镁等指标。

核心结论

  • 研究旨在评估维生素D与镁补充对COVID-19患者临床症状及血清炎症和氧化应激标志物的影响。

研究设计与样本

  • 4臂随机双盲安慰剂对照析因设计临床试验,干预3周。
  • 在伊朗Bandar Abbas的Shahid Mohammadi医院纳入COVID-19住院患者。
  • 纳入标准包括年龄18至65岁、RT-PCR确诊、住院不足48小时、呼吸频率大于30次/分且室内空气氧饱和度低于93%等。
  • 排除标准包括妊娠或哺乳、近一月服用维生素D或镁补充剂、肾衰竭或透析、严重肝病或肝硬化、高钙血症、基线维生素D高于80 ng/ml、基线镁高于2.6 mg/dl等。
  • 共104例合格患者按1:1:1:1随机分为四组各26例。

主要发现

  • A组:维生素D(研究开始时两粒50000 IU胶囊,第4天两粒50000 IU胶囊,第11天一粒50000 IU胶囊,第17天一粒50000 IU胶囊)加镁300 mg/天。
  • B组:维生素D胶囊加镁安慰剂。
  • C组:镁补充剂加维生素D安慰剂。
  • D组:维生素D安慰剂加镁安慰剂。
  • 主要结局包括临床症状缓解(发热、干咳、气短、头痛、肌痛、氧饱和度和死亡率)及CRP、MDA、TAC、WBC、中性粒细胞计数、淋巴细胞计数、中性粒细胞与淋巴细胞比值、25羟维生素D和镁水平。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aims to evaluate the effect of vitamin D and magnesium supplementation on clinical symptoms and serum inflammatory and oxidative stress markers in patients with COVID-19. TRIAL DESIGN: This study is a 4-arm randomized, double-blind, placebo-controlled clinical trial with a factorial design and the intervention period is 3 weeks. PARTICIPANTS: This study is conducted on COVID-19 patients admitted to the Shahid Mohammadi hospital in Bandar Abbas, Iran, who are eligible for inclusion in the study. Patients are included only if they meet all of the following criteria: (1) aged from 18 to 65 years old; (2) confirmation of COVID-19 by RT-PCR test; (3) completing informed consent; (4) passing less than 48 h since the patient's hospitalization; (5) no skin or gastrointestinal allergies due to taking multivitamin supplements, vitamin D, and magnesium; and (6) having more than 30 breaths per minute and less than 93% oxygen saturation in room air and sea level. Patients are excluded if they have any of the following conditions: (1) pregnancy or lactation; (2) taking a daily multivitamin or take a vitamin D or magnesium supplement in the last month; (3) participating in other clinical trials; (4) renal failure or dialysis, severe liver disease or cirrhosis; (5) known diagnosis of hypercalcemia; (6) discharging from the hospital less than 24 h after the start of the intervention; (7) history of kidney stones in the last year; (8) transfer the patient to the ICU; (9) baseline vitamin D levels above 80 ng/ml; (10) baseline magnesium levels above 2.6 mg/dl; and (11) unwillingness of the patient to continue the study. INTERVENTION AND COMPARATOR: Participants will be randomly allocated to one of the four following groups: (A) vitamin D (two 50,000 IU capsules at the beginning of the study, two 50,000 IU capsules on the 4th day, one 50,000 IU capsule on the 11th day, and one 50,000 IU capsule on the 17th day) and magnesium supplement (300 mg/day); (B) vitamin D capsule and magnesium placebo; (C) magnesium supplement and vitamin D placebo; and (D) vitamin D placebo and magnesium placebo. MAIN OUTCOMES: The resolution of clinical symptoms (fever, dry cough, shortness of breath, headache, myalgia, oxygen saturation, and mortality rate) and interpretation of laboratory assays (CRP, MDA, TAC, WBC, neutrophils count, lymphocytes count, ratio of neutrophils to lymphocytes, levels of 25 hydroxyvitamin D and magnesium) will be assessed in the study groups. RANDOMIZATION: A computer-generated block randomization list is used for randomization. BLINDING (MASKING): Investigators and patients are blinded to group allocation and treatment. A double-blind design is achieved using matched placebos. NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): A total of 104 eligible patients are randomized into four groups of 26 subjects (1:1:1:1 allocation ratio). DISCUSSION: With the rapid prevalence of COVID-19 in recent years, more attention has been paid to effective dietary supplementation to improve clinical symptoms and biochemical parameters in these patients. To our knowledge, this is the first study to evaluate the effects of vitamin D supplementation in combination with magnesium or alone with respect to this infectious disease. The findings of the current RCT will provide evidence regarding the effectiveness of dietary supplementation strategies to improve COVID-19 outcomes. TRIAL STATUS: Ethical approval of the first version of the study protocol was obtained from the medical ethics committee of Hormozgan University of Medical Sciences, Bandar Abbas, Iran on May 30, 2021 (IR.HUMS.REC.1400.085). Currently, the recruitment phase is ongoing since August 23, 2021, and is anticipated to be complete by the end of August 2022. TRIAL REGISTRATION: The study protocol was registered in the Iranian Registry of Clinical Trials ( https://www.irct.ir ; IRCT20210702051763N1) on August 14, 2021. https://www.irct.ir/trial/57413 FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ramezani-Jolfaie N, Eftekhar E, Dadinasab M, et al. The effect of vitamin D and magnesium supplementation on clinical symptoms and serum inflammatory and oxidative stress markers in patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials. 2023. PMID: 36747270. doi:10.1186/s13063-023-07107-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。